

Rutgers Cancer Institute of New Jersey Lymphoma Tumor Board

This activity is provided by Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,
Department of Radiology and Department of Pathology.

Interesting Cases Week of September 19, 2022
Rutgers Cancer Institute of New Jersey
Via Webex (email heather.gee@rutgers.edu for an invite)
September 19, 2022 12:00pm – 1:00pm

Case Presenter
Anu Doraiswamy MD

At the conclusion of this activity, participants should be better able to:

- Improve the care of cancer patients through the exchange of information among participating clinicians
- Promote research on oncology that will continually improve the quality of care for cancer patients
- Monitor and continually improve the quality of care to patients with cancer
- Communicate the importance of a multidisciplinary approach in the management of patients with cancer

Target Audience: This activity is designed for medical oncologists, pharmacists, surgical oncologists, general surgeons, radiation oncologists, radiologists, hematologists, pathologists, physician assistants, nurses, and nurse practitioners.

Accreditation & Designation Statements



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designate this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is awarded 1 contact hour. (60-minute CH)

Pharmacists: This knowledge-based activity qualifies for 1 contact hour (0.1 CEUs) of continuing pharmacy education credit.

Disclosure Declarations

Anu Doraiswamy MD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Anu Doraiswamy MD and Jaqueline Manago MSN have no relevant financial relationships with ineligible companies to disclose. Jiyeon Park, PharmD has the following relevant financial

relationship(s) with ineligible companies: Consultant: RevHealth. All of the relevant financial relationships listed have been mitigated